



Vaccibody AS to present data on VB10.NEO at upcoming Society for Immunotherapy of Cancer Annual Meeting 2019

Vaccibody will present preliminary safety, efficacy and immunogenicity results from its phase 1/2a (DIRECT-01) study of cancer neoantigen DNA vaccine VB10.NEO in patients with locally advanced or metastatic solid tumors

Oslo, Norway, October 07, 2019 – Vaccibody AS today announced that preliminary safety, efficacy and immunogenicity data will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2019 which will be held from November 6-10, 2019 in National Harbor, Maryland.

“We are excited that our abstract presenting Vaccibody’s preliminary VB10.NEO clinical read-outs has been accepted for poster presentation at this year’s SITC Meeting,” said Michael Engsig, CEO of Vaccibody. The poster will be the first presentation to report clinical data from our VB10.NEO cancer neoantigen study and is an important milestone for the company.

Details of the poster presentation:

Title: Preliminary safety, efficacy and immunogenicity results from a phase 1/2a study (DIRECT-01) of cancer neoantigen DNA vaccine VB10.NEO in patients with locally advanced or metastatic solid tumors

Abstract ID: P424

Session Date and Time: Saturday, November 9th 2019, 7:00 am - 8:30 pm local time

About VB10.NEO

VB10.NEO, is a proprietary therapeutic DNA vaccine which uses the patient’s own neoantigens for the personalized treatment of cancer patients. A phase I/IIa neoantigen clinical trial is currently enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial cancer or squamous cell carcinoma of the head and neck.

About Vaccibody

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is now enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell

carcinoma as well as urothelial or squamous cell carcinoma of head and neck. Vaccibody has a collaboration with Nektar Therapeutics, planning to start testing VB10.NEO in combination with bempegaldesleukin (NKTR-214) in squamous cell carcinoma of head and neck. Vaccibody's front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), evaluating the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3) is now complete and has published positive 12 months safety, efficacy and immunogenicity data. Vaccibody has recently started a collaboration with Roche, exploring VB10.16 in combination with their checkpoint inhibitor atezolizumab (Tecentriq®) in up to 50 patients with advanced or recurrent cervical cancer. First patient in this study is expected to be vaccinated in Q1 2020.

www.vaccibody.com

Contact:

CEO Michael Engsig

Vaccibody AS

Cell: +45 6173 1509

mengsig@vaccibody.com